Literature DB >> 15603245

Cost of illness of chronic angina.

Harold S Javitz1, Marcia M Ward, Jennifer B Watson, Mirou Jaana.   

Abstract

BACKGROUND: Angina pectoris is one of the principal manifestations of coronary artery disease (CAD). Chronic angina is a debilitating condition that affects millions of people in the United States.
OBJECTIVE: The objective of the study is to estimate, from a societal perspective, the direct costs of chronic angina in the year 2000.
METHODS: Data on medical utilization related to chronic angina were extracted from National Center for Health Statistics public-use databases and from IMS databases on medications (nitrates, beta-blockers, and calcium channel blockers). National average Medicare reimbursement rates were used to estimate costs. We identified medical utilization related to chronic angina based on International Classification of Diseases, Ninth Revision (ICD-9) codes. When ICD-9 codes that do not explicitly identify angina are used in medical databases, people with chronic angina may be coded as having CAD only. To address this, we developed upper- and lower-boundary estimates of the costs of chronic angina. The lower-boundary estimate is based on diagnoses that narrowly define the presence of chronic angina, and is termed "narrowly defined chronic angina." The upper-boundary estimate is based on diagnoses of CAD.
RESULTS: The lower boundary on the cost of chronic angina is the estimated direct medical cost of narrowly defined chronic angina ($1.9 billion when it is the first-listed diagnosis and $8.9 billion when it is listed in any position). The upper boundary on the cost of chronic angina is the estimated total direct medical cost of CAD, which is $33 billion when it is the first-listed diagnosis and $75 billion when it is listed in any position.
CONCLUSION: These analyses capture the range of direct costs that might be attributed to the care of chronic angina in the United States for the year 2000. Some components of care were not available, and estimated costs will be significantly higher if private payer reimbursement rates are used.

Entities:  

Mesh:

Year:  2004        PMID: 15603245

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  14 in total

Review 1.  A review of the cost of cardiovascular disease.

Authors:  Jean-Eric Tarride; Morgan Lim; Marie DesMeules; Wei Luo; Natasha Burke; Daria O'Reilly; James Bowen; Ron Goeree
Journal:  Can J Cardiol       Date:  2009-06       Impact factor: 5.223

2.  The association of angina pectoris with heart disease mortality among men and women by diabetes status: the Rancho Bernardo Study.

Authors:  Kimbach T Carpiuc; Deborah L Wingard; Donna Kritz-Silverstein; Elizabeth Barrett-Connor
Journal:  J Womens Health (Larchmt)       Date:  2010-08       Impact factor: 2.681

3.  Health Resource Utilization and Direct Costs Associated with Angina for Patients with Coronary Artery Disease in a US Managed Care Setting.

Authors:  Judy Kempf; Erin Buysman; Diana Brixner
Journal:  Am Health Drug Benefits       Date:  2011-09

4.  Direct medical cost of newly diagnosed stable coronary artery disease in Hong Kong.

Authors:  Vivian W Y Lee; Yat Yin Lam; Amy C M Yuen; Shuk Yan Cheung; Cheuk-Man Yu; Bryan P Y Yan
Journal:  Heart Asia       Date:  2013-01-02

5.  Epidemiology of angina pectoris: role of natural language processing of the medical record.

Authors:  Serguei S V Pakhomov; Harry Hemingway; Susan A Weston; Steven J Jacobsen; Richard Rodeheffer; Véronique L Roger
Journal:  Am Heart J       Date:  2007-04       Impact factor: 4.749

Review 6.  Drug Therapy for Stable Angina Pectoris.

Authors:  Talla A Rousan; Sunil T Mathew; Udho Thadani
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

7.  Statin utilization in nursing home patients after cardiac hospitalization.

Authors:  Seema Parikh; William H Shrank; Helen Mogun; Niteesh K Choudhry
Journal:  J Gen Intern Med       Date:  2010-08-17       Impact factor: 5.128

8.  Agreement between patient-reported symptoms and their documentation in the medical record.

Authors:  Serguei V Pakhomov; Steven J Jacobsen; Christopher G Chute; Veronique L Roger
Journal:  Am J Manag Care       Date:  2008-08       Impact factor: 2.229

9.  Ranolazine reduces patient-reported angina severity and frequency and improves quality of life in selected patients with chronic angina.

Authors:  Joseph B Muhlestein; Sharon Grehan
Journal:  Drugs R D       Date:  2013-09

10.  Prevalence of Angina Among Primary Care Patients With Coronary Artery Disease.

Authors:  Daniel M Blumenthal; Sidney E Howard; Jennifer Searl Como; Sandra M O'Keefe; Steven J Atlas; Daniel M Horn; Neil W Wagle; Jason H Wasfy; Robert W Yeh; Joshua P Metlay
Journal:  JAMA Netw Open       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.